MicroRNA-126 and Its Target VCAM-1Dermatitis to Nickel
Alteration of the microRNA-126 Expression: a Possible Mechanism in Allergic Contact Dermatitis to Nickel
1 other identifier
observational
15
1 country
1
Brief Summary
Background. Allergic Contact Dermatitis (ACD) is an inflammatory skin disease mediated by direct contact with allergens as nickel, the most common allergen, that may be related with epigenetic changes. Objective. Evaluate the miR-126 expression and its target VCAM-1, in the skin of patients with ACD to nickel. Methods. Fifteen patients with positive patch test to nickel were included, and the expression of miR-126 and VCAM-1 was evaluated by RT-qPCR.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Mar 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2019
CompletedFirst Submitted
Initial submission to the registry
April 23, 2020
CompletedFirst Posted
Study publicly available on registry
April 28, 2020
CompletedApril 29, 2020
April 1, 2020
8 months
April 23, 2020
April 27, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Expression of miR-126
Relative expression of the miR-126 on skin biopsies from ACD patients
9 months
Study Arms (2)
positive ACD to nickel
Patients with positive epicutaneous patch test to nickel
negative ACD to nickel
Patients with negative epicutaneous patch test to nickel
Eligibility Criteria
Female and male patients with allergic contact dermatitis for more than one year
You may qualify if:
- years of age and older
- Epicutaneous Patch Test positive to Nickel
- without previous treatment within the previous 4 weeks
You may not qualify if:
- Pregnancy
- nursing
- menopause
- consumption of any type of drugs (including anti-inflammatories and hormonal treatments) within the previous 2 months
- coexistence of other dermatoses conditions
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dermatology Department. Hospital Central "Dr. Ignacio Morones Prieto"
San Luis Potosí City, 78210, Mexico
Related Publications (3)
Martins LE, Reis VM. Immunopathology of allergic contact dermatitis. An Bras Dermatol. 2011 May-Jun;86(3):419-33. doi: 10.1590/s0365-05962011000300001. English, Portuguese.
PMID: 21738956BACKGROUNDAhlstrom MG, Thyssen JP, Wennervaldt M, Menne T, Johansen JD. Nickel allergy and allergic contact dermatitis: A clinical review of immunology, epidemiology, exposure, and treatment. Contact Dermatitis. 2019 Oct;81(4):227-241. doi: 10.1111/cod.13327. Epub 2019 Jul 9.
PMID: 31140194BACKGROUNDCerutti C, Edwards LJ, de Vries HE, Sharrack B, Male DK, Romero IA. MiR-126 and miR-126* regulate shear-resistant firm leukocyte adhesion to human brain endothelium. Sci Rep. 2017 Mar 30;7:45284. doi: 10.1038/srep45284.
PMID: 28358058BACKGROUND
Biospecimen
skin biopsies
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Juan P Castanedo-Cazares, MD
Dermatology Department. Hospital Central "Dr. Ignacio Morones Prieto"
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Target Duration
- 9 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Adjunt professor
Study Record Dates
First Submitted
April 23, 2020
First Posted
April 28, 2020
Study Start
March 1, 2019
Primary Completion
November 1, 2019
Study Completion
November 30, 2019
Last Updated
April 29, 2020
Record last verified: 2020-04